<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017043</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068644</org_study_id>
    <secondary_id>BMS-MSKCC-01011</secondary_id>
    <secondary_id>MSKCC-01011</secondary_id>
    <secondary_id>NCI-G01-1949</secondary_id>
    <nct_id>NCT00017043</nct_id>
  </id_info>
  <brief_title>BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy</brief_title>
  <official_title>A Phase II Study of Epothilone Analog BMS-247550 in Patients With Metastatic Gastric Adenocarcinoma Previously Treated With a Taxane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who&#xD;
      have metastatic stomach cancer previously treated with chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical activity of BMS-247550, in terms of response rate, in patients&#xD;
           with previously treated metastatic gastric adenocarcinoma.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Assess the response duration, time to progression, and survival of patients treated with&#xD;
           this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive BMS-247550 IV over 1 hour on day 1. Treatment repeats every 21 days for 2-18&#xD;
      courses in the absence of disease progression or unacceptable toxicity. Patients with a&#xD;
      complete response (CR) receive 4 additional courses after confirmation of CR.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 21-58 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma originating in the stomach or gastroesophageal&#xD;
             junction&#xD;
&#xD;
               -  Failed prior taxane-based chemotherapy regimen* in the metastatic setting OR&#xD;
&#xD;
               -  Relapsed within 6 months of completing taxane-based chemotherapy* in the adjuvant&#xD;
                  setting&#xD;
&#xD;
          -  Bidimensionally measurable metastatic disease&#xD;
&#xD;
               -  No prior radiotherapy to only measurable target lesion&#xD;
&#xD;
          -  No squamous cell or sarcomatous disease&#xD;
&#xD;
          -  No known brain metastases NOTE: *Regimen must have included a fluopyrimidine and/or a&#xD;
             platinum drug&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 125,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No unstable angina, myocardial infarction, or congestive heart failure within the past&#xD;
             6 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy within the past 2 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No serious concurrent infection&#xD;
&#xD;
          -  No nonmalignant uncontrolled medical illness that would preclude study&#xD;
&#xD;
          -  No psychiatric disorder or other condition that would preclude study compliance&#xD;
&#xD;
          -  No neuropathy (neuromotor or neurosensory) of grade 2 or greater&#xD;
&#xD;
          -  No known severe hypersensitivity to agents containing Cremophor EL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after the&#xD;
             study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  Prior neoadjuvant and adjuvant chemotherapy allowed&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy except hormone replacement therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to major bone marrow-containing areas (e.g., pelvis or lumbar&#xD;
             spine)&#xD;
&#xD;
          -  No concurrent therapeutic radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 1 week since prior minor surgery and recovered&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent experimental anticancer medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manish A. Shah, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>September 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2003</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2013</last_update_posted>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

